

presentation, clinicopathological abnormalities, treatment, and SDMA concentration pre- (PLE-T0) and post- (PLE-T1) treatment were recorded.

Results: At baseline, SDMA concentration was greater in PLE (T0 14.4 ± 3.09 $\mu\text{g/dL}$) than control (11.3 ± 3.17 $\mu\text{g/dL}$) dogs ($P < 0.001$, Hedge's G 0.98), but decreased with treatment (PLE-T1: 10.1 ± 2.73 $\mu\text{g/dL}$; T0 vs. T1: $P = 0.003$, Hedge's G 1.14). Creatinine concentration was similar in PLE (T0 68 ± 22.4 $\mu\text{g/dL}$) and control (77 ± 21.3 $\mu\text{g/dL}$) dogs at baseline ($P = 0.122$, Hedge's G 0.41). Albumin concentration was less in PLE (17.0 ± 5.56 g/L) than control (29.5 ± 5.12 g/L) dogs ($P < 0.001$, Hedge's G 2.33) before treatment, but increased with treatment (PLE-T1: 23.3 ± 6.34 g/L; T0 vs. T1: $P = 0.001$, Hedge's G 1.09), although remained less than the concentration in controls ($P = 0.001$, Hedge's G 1.14). No other clinicopathological differences were evident.

Conclusions and Clinical Importance: Similar to people with IBD, SDMA may be increased in dogs with PLE, the clinical significance of which requires further investigation.

Comparison of serum symmetric dimethylarginine (SDMA) concentrations in dogs with protein losing enteropathy before (PLE-T0) and after (PLE-T1) treatment, and control dogs.

Abstract GI25: Possible Role of Dietary N-glycolyneuraminic Acid and Dysbiosis in Canine Enteropathy Pathogenesis

Giacomo Rossi¹; Lucia Biagini, DVM¹; Sara Ricci², DVM, PhD; Daniela Oliviero³; Livio Galosi¹; Sinem Gultekin¹; Matteo Cerquetella¹; Alessandra Gavazza¹; Barbara Simionati⁴; Ilaria Patuzzi⁴; Fiorella Carnevali⁵

¹University of Camerino, Camerino, Italy; ²University of Veterinary Medicine Vienna, Vienna, Austria; ³Biessea, Milan, Italy; ⁴EUBIOME, Padova, Italia; ⁵ENEA, Santa Maria di Galeria, Italy

Background: N-glycolyneuraminic acid (Neu5Gc) is synthesized from its N-acetyl precursor (Neu5Ac) by cytidine-5'-monophospho-N acetylneuraminic acid hydroxylase (CMAH). Absent in humans and ferrets, it is polymorphic in dogs. Loss of the CMAH gene generate a change in the structural profile of glycans of all tissues inducing the production of antibodies against Neu5Gc-glycans.

Hypothesis/Objectives: Prolonged uptake of Neu5Gc by negative-CMAH dog through red meat and dairy products from +CMAH mammals leads to a progressive Neu5Gc-glycans incorporation in host's tissue (xenosialization), particularly if the gut microbiota is altered in de-sialilating bacteria determining an inflammatory reaction ("Xenosialitis").

Animals: For immunohistochemistry, gastro-entero-colic biopsies from archive material belonging to European, Asian, and American breeds were analyzed (35 dogs per group). Also, the fecal microbiota of 2 cohorts (127+167) of healthy and enteropathic dogs was evaluated.

Methods: We chose a polyclonal antibody (Creative Diagnostic, DMABH-C003) for Neu5GC expression. The distribution of desializing bacteria was performed using two different sequencing techniques for different regions of the 16S rRNA gene.

Results: Neu5Gc resulted mainly expressed in colon of dogs with enteropathy ($P < 0.005$) with no relation to breed. Greater prevalence of Clostridiales and Bacteroidales was observed in enteropathic dogs.

Conclusions and Clinical Importance: Dysbiosis with increase Clostridiales and Bacteroidales could predispose to xenosialization and intestinal inflammation in negative-CMAH dogs, with a possible greater desializing activity compared to healthy dogs. Increased Neu5GC could cause greater uptake of xenosialoantigens by enteropathic dogs since Bifidobacteria, known for their cross-feeding of sialic acids activity, did not differ between healthy and pathologic.




Figure 1. Fecal microbiota of dogs: (A) relative abundance of Clostridiales (sequencing of regions V3-V4); (B) relative abundance of Clostridiales and Bacteroidales (sequencing of regions V2-V9).




Figure 2. Relative abundance of Bifidobacteriaceae (sequencing of regions V2-V9).

Abstract GI26: Blood Microbiome in Dogs With Chronic Enteropathies: The Future of Prevention and Diagnosis?

Elisa Scarsella¹; Guillaume Jospin², MSc; Niokhor Dione³, DVM, PhD; Holly Ganz⁴, PhD

¹AnimalBiome, Oakland, CA, USA; ²Bioinformatician, AnimalBiome, Oakland, CA, USA; ³Senior Director of Microbial Discovery, AnimalBiome, Oakland, CA, USA; ⁴Chief Science Officer, AnimalBiome, Oakland, CA, USA

Background: The presence of bacteria in the blood has been often associated with an infection. However, recent studies have found bacterial DNA in the blood of healthy subjects. Currently, several hypotheses support the existence of a blood microbiome also in healthy hosts.

Objectives: The aim of this study is to characterize the blood microbiome of healthy dogs and dogs with chronic enteropathies (CE), and to correlate targeted microorganisms observed in blood and stool samples with ongoing disease. The final purpose is to assess a list of detectable blood bacteria correlated with different levels of the gut inflammation, that are possible to evaluate during a chronic pathology.

Animals: 17 healthy dogs and 19 CE dogs.

Methods: Blood and fecal samples were collected from healthy and diseased dogs and analyzed for the full 16S rRNA gene, though PacBio long-read high-throughput sequencing.

Results: Alpha and beta diversities of fecal microbiome were significantly different between the two groups of dogs. Principal components analysis revealed that healthy and sick subjects were

significantly clustered, for both blood and fecal microbiome samples. Some of the taxa shared between blood and stool samples were further analyzed through quantitative Real Time PCR, in order to get the true picture of their abundances. Further studies are needed to confirm the origin of the blood microbiome.

Conclusions: The characterization of a core microbiome in the blood of domestic dogs has potential for use as a diagnostic tool to monitor for the development of gastro-intestinal disease.

Abstract GI27: Occurrence of Owner-Reported Gastrointestinal Disease in 33,172 Dogs in the Dog Aging Project Pack

Sarah M. Schmid¹; Jessica Hoffman², PhD; Emily Gould³, DVM, MS, DACVIM (SAIM), PhD; Alaina Moon⁴, DVM, DACVIM (SAIM); Kate Creevy⁵, DVM, MS, DACVIM (SAIM)

¹University of Tennessee, Knoxville, TN, USA; ²Assistant Professor, Augusta University, Augusta, GA, USA; ³Assistant Professor, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA; ⁴Veterinary Internist, Olympia Veterinary Specialists, Olympia, WA, USA; ⁵Professor, Texas A&M University, College Station, TX, USA

Background: The prevalence of gastrointestinal (GI) disorders in the general owned USA dog population is unknown.

Objective: To determine the occurrence and demographic features of GI disease in dogs enrolled in the Dog Aging Project (DAP) Pack.

ANIMALS.

33,172 dogs